Last reviewed · How we verify

NCT05167006

Effects of Perfetti's Method on Cognition, Dexterity and Sensory Motor Function of the Upper Extremity in Stroke Patients

Status unknown NA Last updated 13 January 2022
What this trial tests

NA trial testing routine physical therapy in Cerebrovascular Accident in 88 participants. Status unknown.

Timeline
6 December 2021
Primary endpoint
15 September 2022
15 October 2022

Quick facts

Lead sponsorUniversity of Lahore
PhaseNA
StatusStatus unknown
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingdouble
Primary purposetreatment
Enrollment88
Start date6 December 2021
Primary completion15 September 2022
Estimated completion15 October 2022
Sites1 location across Pakistan

Drugs / interventions tested

Conditions studied

Sponsor

University of Lahore

Who can join

Eligibility, any sex, with Cerebrovascular Accident. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Null Hypothesis (HO) There is no difference between the effects of Perfetti's Method versus routine physical therapy on cognition, dexterity, and sensory motor function of the upper extremity in stroke patients. Alternate Hypothesis (HA) There is a difference between the effects of Perfetti's Method versus routine physical therapy on cognition, dexterity, and sensory motor function of the upper extremity in stroke patients.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of routine physical therapy

Trials testing the same drug.

Other recruiting trials for Cerebrovascular Accident

Currently open trials in the same condition.

Other University of Lahore trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05167006.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing